Yoon-Pin LIM

Assistant Professor


Assistant Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS.
Adjunct Scientist, Bioinformatics Institute, A*STAR.
Adjunct Scientist, Singapore Eye Research Institute.
Faculty, NUS Graduate School of Integrative Sciences and Engineering.
Affiliate, National University Cancer Institute of Singapore.
Teaching Faculty, Division of Graduate Medical Studies, Yong Loo Lin School of Medicine, NUS.


Degree and Institution Year(s)
National University of Singapore 1990 - 1994
Institute of Molecular and Cell Biology, A*STAR 1994 - 1999

Professional Experience

Position and Institute Year(s)
Dana-Farber Cancer Institute, Boston, USA 1999 – 2000
National Cancer Centre of Singapore 2001 – 2004
Oncology Research Institute/Cancer Science Institute 2005 – 2011

Research Interest

Lim Yoon Pin is one of pioneers to develop and apply cutting-edge liquid chromatography/mass spectrometry-based phosphoproteomic technologies to oncogenic signalling and cancer research. He has published 40 peer-reviewed articles in the area of signal transduction, cancer research and biomarker discovery. He holds 3 patents from USA, China and Singapore while 10 patent applications are pending award. Two of his inventions are licensed to an MNC and SME. Through phosphoproteomics, he discovered WBP2, WW domain binding protein 2, to be a novel breast cancer associated protein and a substrate of the well-known EGF Receptor Tyrosine Kinase oncogene. Subsequently, he demonstrated WBP2 to be an oncogene that works by activating multiple oncogenic pathways such as Estrogen Receptor and Wnt signalling. His lab is expanding WBP2 research to other epithelial cancers and signalling pathways like Hippo signalling. Along with Hong Wanjin, Lim Yoon Pin is considered to be the first to prove WBP2 as a breast cancer oncogene. His lab’s efforts in WBP2 research and its impact on the Wnt and Hippo signalling are recognised internationally. He works with collaborators from Australia, Germany, USA and Singapore.

Lim Yoon Pin’s laboratory focuses on:

  • Signal Transduction of RTKs, Wnt and Hippo pathways
  • Epithelial Cancer Research
  • Biomarker and Drug target Discovery
  • Proteomics and Phosphoproteomics Technologies

Selected Publications

  1. Lim SK, Lu S, Kang SA, Tan HJ, Li Z, Wee ZNA, Guan JS, Chichili VPR, Sivaraman J, Putti TC, Thike AA, Tan PH, Sudol M, Virshup DM, Chan SW, Hong WJ and Lim YP. Wnt Signaling Promotes Breast Cancer By Blocking ITCH-Mediated Degradation of YAP/TAZ transcription Co-activator WBP2. 2016 Cancer Res. 76(21):6278-6289

  2. Lee WH, Choong LY, Mon NN, Lu SY, Liew CS, Tan KY, Lin QS, Pang MF, Pan M, Pang B, Krishna SRV, Druker BJ, OW GS, Kuznetsov V, Tan TZ, Goh LK, Thiery JP, Tan PBO, Lim CT, Harteneck C and Lim YP. TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. 2016 Sci. Rep. 6:27903

  3. Jiang H, Hu H, Lin F, Lim YP, Hua F, Tong X, Zhang S. S100P is overexpressed in squamous cell and adenosquamous carcinoma subtypes of endometrial cancer and promotes cancer cell proliferation and invasion. 2016 Cancer Invest. 34(10):477-488

  4. Hou A, Law KP, Tan MQ, Lim YP, Tong L. In vitro Secretomics study of Pterygium-derived Fibroblasts by iTRAQ-based Quantitative Proteomics Strategy. Exp Eye Res 2016 153:14-22

  5. Toh CXD, EL Farran CA, Chong ZS, Wang HF, Tan YS, Maury JJ, Guo HC, Ma D, Goh GYL, Chang YT, Collins JJ, Daley GQ, Li H, Lim YP, Bard FA, Loh YH. Global Regulators Controlling Human Somatic Cell Reprogramming. 2016 Cell Reports. 15(12):2597-2607

  6. Lin F, Li Z, Hua Y, Lim YP. Proteomic profiling predicts drug response to novel targeted anti-cancer therapeutics. 2016 Expert Rev. Proteomics. 13(4):411-20

  7. Mulina, Lu S, Chong PK, Yeoh KG and Lim YP. Comparative proteomic profiling of extracellular proteins between normal and gastric cancer cells. 2015 Current Cancer Drug Target. 16(5):442-54

  8. Iyengar P, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, Verma C, Seoane J, and Eichhorn P. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. 2015 Sci. Rep. 5:14733

  9. Man X, Megraw TL, Lim YP. Cep68 can be regulated by by Nek2 and SCF complex. 2015 Eur. J. Cell. Biol. 94:162–172

  10. Goh WQJ, Ow GS, Kuznetsov V, Chong PK, Lim YP. DLAT Subunit of the Pyruvate Dehydrogenase Complex is Upregulated in Gastric Cancer – implications in cancer therapy. 2015 Am J Transl. Res. 7(6):1140-1151

  11. Hay SH, Shin EM, Lee MH, Goh JN, Ong HT, Arkasubhra G, Wong M, Ong CW, W Sun, Kong X, Salto-Tellez M, Putti TC, Lim CT, Lobie PE, Lim YP, YAP CT, Sethi Gautam, Lee M, Tan P, Miller LD, Hui K, Zhu T, Miyamoto S, Kumar AP, Tergaonkar V. Dead-box DP103, an essential regulator of NEMO SUMOylation and NF-kB activation, defines the metastatic potential of human breast cancer. 2014 J. Clin. Invest. 124(9):3807-24 (5-year IF: 14.7)

  12. Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer. 2014 Cell Reports 8, 1–13, (IF: 7.2)

  13. Hou A, Lan W, Law KP, Khoo SC, Tin MC, Lim YP, Tong L. Evaluation of global differential gene and protein expression in primary pterygium: S100A8 and S100A9 as possible drivers of a signaling network. 2014 PLoS One 13;9(5):e97402 (5-year IF: 4.24)

  14. Cao X, Kong CM, Mathi KM, Lim YP, Cacheux-Rataboul V, Wang Xueying. The use of transformed IMR90 cell model to identify the potential extra-telomeric effects of hTERT in cell migration and DNA damage response. 2014 BMC Biochemistry 15(1):17

  15. See LP, Lu S, Chong PK and Lim YP. Increased secretion of CXCL3 as breast cancer cells acquire metastasis potential. 2014 Current Cancer Drug Target Mar;14(3):294-309 (5-year IF: 4.4)

  16. Lin F, Tan HJ, Guan JS and Lim YP. Divide and Conquer – (Invited) Subproteomic Approaches toward Gastric Cancer Biomarker and Drug Target Discovery. 2014 Expert Rev. Proteomics 11(4):515-30 (5-year IF: 3.6)

  17. Tan HK, Toh CXD, Ma D, Yang B, Tan TK, Lim YP, Cook SA, Loh YH. Rapid and efficient reprogramming with sub-milliliter volumes of human peripheral blood cells. 2014 Stem Cells Transl. Med. May;3(5):586-98

  18. Law KP and Lim YP. Recent Advances in Mass Spectrometry – Data Independent Analysis and Hyper Reaction Monitoring. Expert Rev Proteomics. 2013 Dec;10(6):551-66

  19. Lim UM, Yap MG, Lim YP, Goh LT, Ng SK. Identification of Autocrine Growth Factors Secreted by CHO cells for Applications in Single Cell Cloning Media. 2013 J Proteome Res. Jul 2013; 12(7): 3496-510 .

  20. Yang, Yixuan; Toy, Weiyi; Choong, Lee Yee; Hou, Peiling; Ashktorab, Hassan; Smoot, Duane; Yeoh, Khay Guan; Lim, Yoon-Pin. Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker – implications in molecular imaging. J Proteome Res 2012 Dec 7;11(12):5736-47.

  21. Assiddiq BF, Tan KY, Toy W, Chan SP, Chong PK, Lim YP. EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth. J Proteome Res. 2012 Aug 3;11(8):4110-9

  22. Manjeet M, Soah YC, Ng C, Yusoff P, Rebecca A. Jackson, Yew JX, Yim D, Iyu A, Koh XW, Risgar NF, Li D, Saravanan S, Lim YP, Guy GR and Sivaraman J. A novel dimer consisting of a pair of RING domains and Zinc finger domains constitutes the phosphotyrosine-binding domain of the Hakai Ubiquitin E3 ligase protein that targets E-Cadherin, Cortactin and other Src substrates. 2012 EMBO J 31(5):1308-19 (5 year IF: 9.4)

  23. Lim SK, Orhant-Prioux M, Toy W, Tan KY and Lim YP. Tyrosine Phosphorylation of Transcription Coactivator WW-Domain Binding Protein 2 Regulates Estrogen Receptor α Function in Breast Cancer via Wnt Crosstalk. 2011 FASEB J. Sep;25(9):3004-18. Epub 2011 Jun 3 (5-year IF: 7.2)

  24. Choong LY, Lim S, Lim SK, Chen Y, Lee H, Loh MCS, Chong PK, Wong CY, Chan SP, Salto-Tellez M, Shah N and Lim YP. Elevated NRD1 Metalloprotease Expression Plays A Role in Breast Cancer Growth and Proliferation. 2011 Genes Chromosomes & Cancer 50(10):837-47 (5-year IF: 3.8)

  25. Choong LY and Lim YP. Biological models for breast cancer – One size does not fit all. 2011 Expert Rev. Proteomics 8(1): 5-7 (5-year IF: 3.7)

  26. Chong PK, Lee HY, Loh MCS, Lim WT, Chan SP, Soo RA and Lim YP. Hemoglobin subunit beta (HBB) is a potential biomarker for predicting response to Gefitinib in NSCLC patients. 2011 J Integr Omics. 1(2): 298-305

  27. Yang Y, Lim SK, Choong LY, Lee HY, Chen Y, Chong PK, Hassan A, Wang T, Salto-Tellez M, Yeoh KG and Lim YP. Cathepsin S mediates Gastric Cancer Cell Migration and Invasion via a network of metastasis-associated proteins. 2010 J. Proteome. Res. 9(9):4767-78. (5-year IF: 5.6)

  28. Chong PK, Lee HY, Loh MCS, Lin Q, So J, Lim KH, Soo RA, Yong WP, Chan SP, Smoot DT, Hassan A, Yeoh KG and Lim YP. Up-regulation of plasma C9 protein in gastric cancer patients. 2010 Proteomics 10(18):3210-21. (5-year IF: 4.9)

  29. Chong, PK, Lee, HY, Zhou J, Liu SC, Loh, MCS, Wang TT, Chan SP, Smoot DT, Ashktorab H, So, JBY, Lim KH, Yeoh KG and Lim YP. ITIH3 is a potential biomarker for early detection of gastric cancer. 2010 J. Proteome Res. 9(7)-3671–3679 (5-year IF: 5.6)

  30. Chong PK, Lee HY, Zhou J, Liu SC, Loh MCS, So JBY, Lim KH, Yeoh KG and Lim YP. Reduced plasma APOA1 level is associated with Gastric Tumor Growth in MKN45 mouse xenograft model. 2010 J. Proteomics 73(8):1632-1640 (5-year IF: 5.1)

  31. Choong LY, Lim S, Chong PK, Wong CY, Shah N and Lim YP. Proteome-wide profiling of the MCF10AT breast cancer progression model. 2010 PLoS One Jun 9;5(6):e11030 (5-year IF: 4.6)

  32. Toy Weiyi, Lim SK and Lim YP. EGF-induced tyrosine phosphorylation of Endofin is dependent on PI3K activity and proper localization to endosomes. 2009 Cell. Signal. 22, pp. 437-446 (5-year IF: 4.1)

  33. Lim S, Choong LY, Chong PK, Chen Y and Lim YP. Regulation of Macrophage Inhibitory Factor (MIF) by Epidermal Growth Factor Receptor (EGFR) in the MCF10AT model of breast cancer progression. 2009 J. Proteome Res. 8(8): 4062-4076 (5-year IF: 5.74)

  34. Ho J*, Kong WFJ*, Choong LY*, Loh MCS, Toy W, Chong PK, Wong CH, Wong CY, Shah N and Lim YP. Novel Breast Cancer Metastasis-associated proteins. 2009 J. Proteome Res. 8(2):583-594 (5-year IF: 5.74)

  35. Chong PK, Lee H, Kong WF, Loh MCH, Wong CH and Lim YP. Phosphoproteomics, Oncogenic signalling and Cancer Research (Invited Review). 2008 Proteomics 8, 4370-4382 (5-year IF: 5.19)

  36. Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, Albert DH, Davidsen SK, Chen CS. Synergistic anti-leukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. 2008 Leukemia 22, 138–146 (5-year IF: 6.89)

  37. Chen Y, Choong LY, Lin QS, Philps, R, Wong CH, Ang BK, Loh MCS, Hew CL, Shah, N, Druker BJ, Chong PK and Lim YP. Differential expression of novel tyrosine kinase substrates during breast cancer development. 2007 Mol. Cell. Proteomics 6(12):2072-87 (5-year IF: 9.39)

  38. Choong LY, Lim S, Loh MCS, Man X, Chen Y, Toy W, Tan YL, Pang M, Chen CS, Poonepalli A, Hande PM, Tan PH, Salto-Tellez M, Wong CY, Shah N, Druker BJ and Lim YP. Progressive loss of EGFR in a sub-population of breast cancers – implications in target-directed therapeutics. 2007 Mol. Cancer Ther. 6(11):2828–42 (5-year IF: 5.43)

  39. Chen YH*, Low TY*, Choong LY, Rajarshi Sankar Ray, Tan YL, Toy Weiyi, Lin QS, Ang BK, Wong CH, Lim Simin, Li B, Hew CL, Sze NSK, Druker BJ and Lim YP. Phosphoproteomics identified Endofin, DCBLD2 and KIAA0582 as novel targets of EGF signaling and Gefitinib in human cancer cells. 2007 Proteomics 7, 2384–2397 (5-year IF: 5.19)

  40. Lim YP. Mining the tumor phosphoproteome for molecular cancer markers. 2005 Clin Cancer Res. 11: 3163-3169. (5-year IF: 6.65)

  41. Lim YP, Wong CY, Ooi LL, Druker BJ and Epstein RJ. Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. 2004 Clin. Cancer Res. 10:3980-3987. (5-year IF: 6.65)

  42. Lim YP, Diong LS, Qi R, Druker, BJ and Epstein, RJ. Phosphoproteomic fingerprinting of growth factor signaling and anticancer drug action in human tumor cells. 2003 Mol. Cancer Ther. 2(12): 1369-1377. (5-year IF: 5.43)

  43. Lim YP, Low BC, Lim J, Wong ES, Guy GR. Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling. 1999 J. Biol. Chem. Jul 2;274(27):19025-34. (5-year IF: 5.57)

  44. B C Low, Lim YP, Lim J, Wong ES, Guy GR. Tyrosine phosphorylation of the Bcl-2-associated protein BNIP-2 by fibroblast growth factor receptor-1 prevents its binding to Cdc42GAP and Cdc42. 1999 J. Biol. Chem. Nov 12;274(46):33123-30. (5-year IF: 5.57)

  45. Lim YP, Low BC, Ong SH, Guy GR. Growth factors stimulate tyrosine dephosphorylation of p75 and its dissociation from the SH2 domain of Grb2. 1997 J. Biol. Chem. Nov 21;272(47):29892-8. (5-year IF: 5.57)

  46. Ong SH, Lim YP, Low BC, Guy GR. SHP2 associates directly with tyrosine phosphorylated p90 (SNT) protein in FGF-stimulated cells. 1997 Biochem. Biophys. Res. Commun. Sep 8; 238(1):261-6. (5-year IF: 2.82)

  47. Ong SH, Goh KC, Lim YP, Low BC, Klint P, Claesson-Welsh, Cao X, Tan YH, Guy, GR. Suc1-associated neurotrophic factor target (SNT) protein is a major FGF-stimulated tyrosine phosphorylated 90-kDa protein which binds to the SH2 domain of GRB2. 1996 Biochem. Biophys. Res. Commun. Aug 23; 225(3):1021-6. (5-year IF: 2.82)

  48. Goh KC*, Lim YP*, Ong SH, Siak CB, Cao X, Tan YH, Guy GR. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor-stimulated cells, as 80K-H. 1996 J. Biol. Chem. Mar 8;271(10):5832-8. (5-year IF: 5.57)